Carnitine-acylcarnitine translocase deficiency

WikiDoc Resources for Carnitine-acylcarnitine translocase deficiency
Articles
Most recent articles on Carnitine-acylcarnitine translocase deficiency Most cited articles on Carnitine-acylcarnitine translocase deficiency Review articles on Carnitine-acylcarnitine translocase deficiency Articles on Carnitine-acylcarnitine translocase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Carnitine-acylcarnitine translocase deficiency Images of Carnitine-acylcarnitine translocase deficiency Photos of Carnitine-acylcarnitine translocase deficiency Podcasts & MP3s on Carnitine-acylcarnitine translocase deficiency Videos on Carnitine-acylcarnitine translocase deficiency
Evidence Based Medicine
Cochrane Collaboration on Carnitine-acylcarnitine translocase deficiency Bandolier on Carnitine-acylcarnitine translocase deficiency TRIP on Carnitine-acylcarnitine translocase deficiency
Clinical Trials
Ongoing Trials on Carnitine-acylcarnitine translocase deficiency at Clinical Trials.gov Trial results on Carnitine-acylcarnitine translocase deficiency Clinical Trials on Carnitine-acylcarnitine translocase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Carnitine-acylcarnitine translocase deficiency NICE Guidance on Carnitine-acylcarnitine translocase deficiency NHS PRODIGY Guidance FDA on Carnitine-acylcarnitine translocase deficiency CDC on Carnitine-acylcarnitine translocase deficiency
Books
Books on Carnitine-acylcarnitine translocase deficiency
News
Carnitine-acylcarnitine translocase deficiency in the news Be alerted to news on Carnitine-acylcarnitine translocase deficiency News trends on Carnitine-acylcarnitine translocase deficiency
Commentary
Blogs on Carnitine-acylcarnitine translocase deficiency
Definitions
Definitions of Carnitine-acylcarnitine translocase deficiency
Patient Resources / Community
Patient resources on Carnitine-acylcarnitine translocase deficiency Discussion groups on Carnitine-acylcarnitine translocase deficiency Patient Handouts on Carnitine-acylcarnitine translocase deficiency Directions to Hospitals Treating Carnitine-acylcarnitine translocase deficiency Risk calculators and risk factors for Carnitine-acylcarnitine translocase deficiency
Healthcare Provider Resources
Symptoms of Carnitine-acylcarnitine translocase deficiency Causes & Risk Factors for Carnitine-acylcarnitine translocase deficiency Diagnostic studies for Carnitine-acylcarnitine translocase deficiency Treatment of Carnitine-acylcarnitine translocase deficiency
Continuing Medical Education (CME)
CME Programs on Carnitine-acylcarnitine translocase deficiency
International
Carnitine-acylcarnitine translocase deficiency en Espanol Carnitine-acylcarnitine translocase deficiency en Francais
Business
Carnitine-acylcarnitine translocase deficiency in the Marketplace Patents on Carnitine-acylcarnitine translocase deficiency
Experimental / Informatics
List of terms related to Carnitine-acylcarnitine translocase deficiency

Carnitine-acylcarnitine translocase deficiency is a rare condition that prevents the body from converting long-chain fatty acids into energy, particularly during periods without food. Carnitine, a natural substance acquired mostly through the diet, is used by cells to process fats and produce energy. People with this disorder have a faulty enzyme that prevents long-chain fatty acids from being transported into the innermost part of the mitochondria for processing.

Presentation

The signs of carnitine-acylcarnitine translocase deficiency usually begin within the first few hours of life. Seizures, an irregular heartbeat, and breathing problems are often the first signs of this disorder. This disorder may also cause extremely low levels of ketones (products of fat breakdown that are used for energy) and low blood sugar (hypoglycemia). Together, these two signs are called hypoketotic hypoglycemia. Other signs that are often present include ammonia in the blood (hyperammonemia), an enlarged liver (hepatomegaly), heart abnormalities (cardiomyopathy), and muscle weakness. This disorder can cause sudden infant death.

Pathiophysiology

Mutations in the SLC25A20 gene lead to the production of a defective version of an enzyme called carnitine-acylcarnitine translocase.

Acyl-CoA from cytosol to the mitochondrial matrix.gif

Without this enzyme, long-chain fatty acids from food and fats stored in the body cannot be broken down and processed. As a result, these fatty acids are not converted into energy, which can lead to characteristic signs and symptoms of this disorder, such as weakness, hypoglycemia, and an irregular heartbeat. Free long-chain fatty acids or those that are joined with carnitine can affect the electrical properties of cardiac cells causing an irregular heart beat (arrhythmia, which can lead to cardiac arrest). Fatty acids may also build up in tissues and can damage the heart, liver, and muscles, and cause more serious complications.

See also

• Primary carnitine deficiency
• Carnitine palmitoyltransferase I deficiency
• Carnitine palmitoyltransferase II deficiency

This article incorporates public domain text from The U.S. National Library of Medicine

Template:WS